Effect of obesity on dolutegravir exposure in Black Southern African adults living with HIV
Conclusion: Dolutegravir exposure was marginally lower in participants with obesity, but this is not clinically significant. Our findings suggest that there is no need to dose adjust dolutegravir in people with obesity.
Source: Southern African Journal of HIV Medicine - Category: African Health Authors: Enkosi Mondleki Source Type: research
More News: African Health | Eating Disorders & Weight Management | Obesity | South Africa Health | Statistics | Viread | Women